Reletter
Artwork for Mission GBM

Evidence | Treatment | Science | Hope for Brain Cancers

Platform
Substack
PricingOnly free issuesPublishesTwice weekly
Issues62Founded4 years agoLast Issue4 months ago
Active

Read this Newsletter

missiongbm.com
Artwork for Mission GBM

Latest Issues

One Year Later…Onward!

Julie passed away from GBM one year ago today (see here). The past year was the “Year of Transition” as we worked to ensure that all the nuts-and-bolts of family affairs were completed, and that our children were moving forward within their...

4 months ago
20

Imvax Reports Phase 2b Trial Data for IGV-001 in ndGBM

On 2-Dec-2025, Imvax reported top line data from its Phase 2b clinical trial of IGV-001 (see here and here).

Bottom Line: IGV-001 missed its pre-specified Primary Endpoint (PEP) of statistically significant extension of Progression Free Su...

6 months ago
14

In Memoriam

Julie passed away peacefully in her sleep on 21-Jan with me by her side.

She lived with GBM for 1141 days (37.5 months), and for most of that Bonus Time she enjoyed a remarkable quality of life.

A brief remembrance of Julie, written by ou...

a year ago
30

Breaking News: FDA Approves Vorasidenib (Voranigo®)

UPDATE: A few hours after we originally posted, Servier updated its Home page and issued a press release about the Vorasidenib approval. See here for further information.

We have had 20-Aug-2024 circled on our calendar for months because i...

2 years ago
7

Postcards from the Field

This little guy was born in our backyard about 12 hours before the photo was taken. We watched his mother walk away and leave him unprotected in full view of predators. Being naive to deer parenting practices, I stayed up all night to make...

2 years ago
12

Key Facts

Contact Information
Newsletter Author
Number of Subscribers
Find out how many people subscribe to this newsletter.

Audience Metrics

Subscribers, engagement, traffic and sponsorship for Mission GBM.

SubscribersEngagement67Monthly Web Visits
Accepts SponsorsEstimated Cost per Ad

Authors

The writers behind this newsletter.

  • Scott L. Rakestraw, PhD

    Husband, Father, Friend, and Biotech Entrepreneur/Investor committed to taking the battle to glioblastoma (GBM) and other brain cancers

  • Frequently Asked Questions

    How can I access the email archive for Mission GBM?

    You can find recent issues that have been published by Mission GBM on Reletter by scrolling up to where it says Latest Issues. Tap on the link for any of the most recent emails or hit More Issues to see older ones.

    How many subscribers does Mission GBM have?

    To see how many people subscribe to Mission GBM, simply upgrade your Reletter account. We provide readership numbers and lots of other stats for this newsletter so you can decide if it's worth reaching out to.

    How can I advertise in Mission GBM?

    Newsletter advertising can be extremely effective when it's done right. Before you pitch Mission GBM as a potential sponsor or partner, make sure that you've done your research and checked its newsletter stats with Reletter.

    Then, personalize one of our winning pitching templates and send it to the right person using the contact info provided.

    How much does it cost to sponsor a publication like Mission GBM?

    Newsletter ad rates (or CPM) vary depending on many factors, including industry, number of subscribers, open rate, ad placement and more.

    To find out how much an ad will cost, contact Mission GBM using the contact information provided and ask for a copy of their media kit.

    How can I find newsletters related to Mission GBM?

    Scroll up to where it says Related Newsletters to see other publications like Mission GBM. You can also search our email newsletter directory to discover other newsletters that cover the topics you're interested in.

    How do I contact Mission GBM?

    Reletter provides this newsletter's website URL above, where you will often find their contact information. We also provide links to associated social media accounts and pitching templates so you can reach out fast.